Suppression of bone morphogenetic protein inhibitors promotes osteogenic differentiation: therapeutic implications
1 Regional North West London Maxillofacial Unit, Northwick Park Hospital, Wattford Road, Harrow, London HA1 3UJ, UK
2 Academic Orthopaedic Unit, Institute of Molecular Medicine, Leeds Medical School, and Leeds General Infirmary Teaching Hospital, Clarendon, Great George Street, Leeds LS1 3EX, UK
Arthritis Research & Therapy 2008, 10:115 doi:10.1186/ar2467
See related research by Kwong et al., http://arthritis-research.com/content/10/3/R65Published: 12 August 2008
Bone morphogenetic proteins (BMPs) are expressed during osteogenesis and their action is regulated by corresponding BMP inhibitors. Chordin (a well recognized BMP inhibitor) and BMP-2 are expressed during osteogenic differentiation of human mesenchymal stem cells. Chordin inhibition induces human mesenchymal stem cell differentiation and reduces their proliferation by increasing BMP-2 bioavailability. The potential of suppressing BMP inhibitors is emerging as a biological therapeutic target in bone tissue engineering, because it results in an unopposed synergy between the various growth factors that are involved in osteogenesis, within their physiological milieu.